JP2009521685A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009521685A5 JP2009521685A5 JP2008547568A JP2008547568A JP2009521685A5 JP 2009521685 A5 JP2009521685 A5 JP 2009521685A5 JP 2008547568 A JP2008547568 A JP 2008547568A JP 2008547568 A JP2008547568 A JP 2008547568A JP 2009521685 A5 JP2009521685 A5 JP 2009521685A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- patient
- fluid sample
- soluble
- csf receptor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US75321805P | 2005-12-22 | 2005-12-22 | |
| PCT/US2006/048879 WO2007120252A2 (en) | 2005-12-22 | 2006-12-21 | Soluble human m-csf receptor and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012043540A Division JP2012108155A (ja) | 2005-12-22 | 2012-02-29 | 可溶性ヒトｍ−ｃｓｆ受容体およびその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009521685A JP2009521685A (ja) | 2009-06-04 |
| JP2009521685A5 true JP2009521685A5 (https=) | 2011-02-10 |
Family
ID=38609972
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008547568A Withdrawn JP2009521685A (ja) | 2005-12-22 | 2006-12-21 | 可溶性ヒトｍ−ｃｓｆ受容体およびその使用 |
| JP2012043540A Pending JP2012108155A (ja) | 2005-12-22 | 2012-02-29 | 可溶性ヒトｍ−ｃｓｆ受容体およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012043540A Pending JP2012108155A (ja) | 2005-12-22 | 2012-02-29 | 可溶性ヒトｍ−ｃｓｆ受容体およびその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20100099123A1 (https=) |
| EP (1) | EP1977238B1 (https=) |
| JP (2) | JP2009521685A (https=) |
| KR (1) | KR101358600B1 (https=) |
| CN (1) | CN101379400A (https=) |
| AU (1) | AU2006342119B8 (https=) |
| CA (1) | CA2634945A1 (https=) |
| WO (1) | WO2007120252A2 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8080246B2 (en) | 2008-11-26 | 2011-12-20 | Five Prime Therapeutics, Inc. | Colony stimulating factor 1 receptor (CSF1R) extracellular domain fusion molecules |
| WO2010062401A2 (en) | 2008-11-26 | 2010-06-03 | Five Prime Therapeutics, Inc. | Treatment of osteolytic disorders and cancer using csf1r extracellular domain fusion molecules |
| EP2950098A1 (en) * | 2009-07-14 | 2015-12-02 | National Institute of Advanced Industrial Science and Technology | Glycan markers as measure of disease state of hepatic diseases |
| RU2427323C1 (ru) * | 2010-02-25 | 2011-08-27 | Федеральное государственное учреждение "Ростовский научно-исследовательский онкологический институт Федерального агентства по высокотехнологичной медицинской помощи" | Способ прогнозирования генерализации процесса при злокачественных опухолях костей |
| MX378336B (es) | 2010-05-04 | 2025-03-10 | Five Prime Therapeutics Inc | Anticuerpos que se unen a factor estimulante de colonias 1 (csf1r). |
| US20130302322A1 (en) | 2012-05-11 | 2013-11-14 | Five Prime Therapeutics, Inc. | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
| ES2442991B1 (es) * | 2012-08-14 | 2014-11-25 | Fundación Md Anderson International España | Método para el diagnóstico y/o pronóstico de linfomas |
| CN107759690A (zh) | 2012-08-31 | 2018-03-06 | 戊瑞治疗有限公司 | 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法 |
| AU2015280362B2 (en) | 2014-06-23 | 2021-03-04 | Five Prime Therapeutics, Inc. | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R) |
| PT3212670T (pt) | 2014-10-29 | 2021-02-15 | Bristol Myers Squibb Co | Terapêutica de combinação para cancro |
| EA201791421A1 (ru) | 2014-12-22 | 2017-10-31 | Файв Прайм Терапьютикс, Инк. | Антитела против csf1r для лечения pvns |
| BR112017020952A2 (pt) | 2015-04-13 | 2018-07-10 | Five Prime Therapeutics Inc | método de tratamento de câncer, composição e uso da composição |
| SG11202001606XA (en) | 2017-09-13 | 2020-03-30 | Five Prime Therapeutics Inc | Combination anti-csf1r and anti-pd-1 antibody combination therapy for pancreatic cancer |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) * | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4929700A (en) * | 1987-04-16 | 1990-05-29 | Cetus Corporation | Production of purified, biologically active, bacterially produced recombinant human CSF-1 |
| AU2728588A (en) * | 1987-10-23 | 1989-05-23 | Genetics Institute Inc. | Composition and method for treating cancers characterized by over-expression of the c-fms proto-oncogene |
| JPH0967400A (ja) * | 1995-08-31 | 1997-03-11 | Toray Ind Inc | モノクローナル抗体、該抗体を産生するハイブリドーマ及びその利用 |
| US6610484B1 (en) * | 1999-01-26 | 2003-08-26 | Cytyc Health Corporation | Identifying material from a breast duct |
| WO2004045532A2 (en) * | 2002-11-15 | 2004-06-03 | Chiron Corporation | Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis |
| US20040209937A1 (en) * | 2003-02-24 | 2004-10-21 | Sugen, Inc. | Treatment of excessive osteolysis with indolinone compounds |
-
2006
- 2006-12-21 CN CNA2006800519125A patent/CN101379400A/zh active Pending
- 2006-12-21 WO PCT/US2006/048879 patent/WO2007120252A2/en not_active Ceased
- 2006-12-21 AU AU2006342119A patent/AU2006342119B8/en active Active
- 2006-12-21 CA CA002634945A patent/CA2634945A1/en not_active Abandoned
- 2006-12-21 KR KR1020087017904A patent/KR101358600B1/ko active Active
- 2006-12-21 EP EP06850597.3A patent/EP1977238B1/en active Active
- 2006-12-21 JP JP2008547568A patent/JP2009521685A/ja not_active Withdrawn
- 2006-12-21 US US12/158,877 patent/US20100099123A1/en not_active Abandoned
-
2012
- 2012-02-29 JP JP2012043540A patent/JP2012108155A/ja active Pending
-
2013
- 2013-02-20 US US13/771,395 patent/US20140030738A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009521685A5 (https=) | ||
| Kim et al. | Expression of cyclooxygenase-1 and-2 associated with expression of VEGF in primary cervical cancer and at metastatic lymph nodes | |
| JP2008530582A5 (https=) | ||
| Mounajjed et al. | Glypican-3 expression in gastrointestinal and pancreatic epithelial neoplasms | |
| JP2008529008A5 (https=) | ||
| Yang et al. | Duodenal gastrointestinal stromal tumor: clinical, pathologic, immunohistochemical characteristics, and surgical prognosis | |
| JP2015516985A5 (https=) | ||
| Welinsky et al. | Familial pancreatic cancer and the future of directed screening | |
| Utsugi et al. | Utility of the monoclonal antibody HIK1083 in the diagnosis of adenoma malignum of the uterine cervix | |
| WO2021209161A1 (en) | Detection of advanced adenoma and/or early stage colorectal cancer | |
| Dang et al. | Comprehensive analysis of 5‐hydroxymethylcytosine in zw10 kinetochore protein as a promising biomarker for screening and diagnosis of early colorectal cancer | |
| CN105074467B (zh) | 提高分子靶向治疗肝细胞癌的敏感性的分析方法 | |
| Anusha et al. | Electrochemical detection of cervical cancer biomarkers | |
| Calistri et al. | Fecal DNA for Noninvasive Diagnosis of Colorectal Cancer in Immunochemical Fecal Occult Blood Test–Positive Individuals | |
| CN115166245A (zh) | Clu及其组合物在诊断胆管癌中的应用及胆管癌诊断试剂盒 | |
| WO2020262429A1 (ja) | がんのバイオマーカーおよびがんの発症を判定する方法 | |
| Nuzhat et al. | Exosomes in pancreatic juice as valuable source of biomarkers for early diagnosis of pancreatic cancer | |
| van Gent et al. | Exploring morphologic and molecular aspects of endometrial cancer under progesterone treatment in the context of fertility preservation | |
| Brioschi et al. | Longitudinal study of CEA and CA125 in ovarian cancer | |
| RU2008130113A (ru) | Растворимый рецептор m-csf человека и его применения | |
| Xuan et al. | Protein expression and gene promoter hypermethylation of CD99 in transitional cell carcinoma of urinary bladder | |
| Khanna et al. | Puneet | |
| Zhan et al. | The diagnostic value of detection of high-risk HPV in differentiating primary bladder cancer versus uterine cervical cancer involving bladder-A case report | |
| US20190086418A1 (en) | Method for the diagnosis of etoposide prodrug treatable cancer | |
| Bhardwaj et al. | Gynecological Coevality: Synchronous Tumors |